{"doi":"10.1002/cncr.70031","title":"Effectiveness and cost of implementing a patient navigation program to increase colorectal cancer screening in a large federally qualified health center","abstract":"INTRODUCTION: The purpose of this study was to evaluate the effectiveness and cost of a patient navigation (PN) program in a large federally qualified health center (FQHC). METHODS: The PN program implemented at AltaMed was evaluated; it is an FQHC that participated in the Centers for Disease Control and Prevention's Colorectal Cancer Control Program. A tailored data collection tool was developed to collect time and resources spent on program activities, salaries of staff, nonlabor resources, and process and outcome measures for 2021-2023. Sociodemographic characteristics and screening uptake for 2020-2023 was collected. Screening uptake and percentage of stool-based tests returned by year and intervention type and compared process measures was calculated, as was the cost of strategies used to increase uptake of stool-based colorectal cancer screening tests. RESULTS: The percentage of fecal immunochemical tests (FIT) returned among those receiving the PN program ranged from 36.6% in 2021 to 51.0% in 2023. The total annual cost for PN, mailings of FITs, and cost of the FIT kits ranged from $328,000 to $388,000 across the 3 years. The FQHC cost per person completing FITs decreased from $32 in 2021 to $25 in 2023. The total cost (FQHC and payer reimbursement) was calculated at $54 in 2021, $44 in 2022, and $47 in 2023 for each person completing FIT. The total cost was $512 in 2022 and $513 in 2023 per person completing Cologuard. CONCLUSION: The PN program, which used reminder texts and calls, alongside mass mailings of stool kits, increased kit returns over the implementation period.","journal":"Cancer","year":2025,"id":572063,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9078,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1315087,"name":"Esmeralda Ruiz","orcid":"0000-0002-2479-3565","position":1,"is_corresponding":false},{"id":1478323,"name":"Raylene Ibarra","orcid":null,"position":2,"is_corresponding":false},{"id":1477980,"name":"Sharon Hudson","orcid":"0000-0002-5955-7327","position":3,"is_corresponding":false},{"id":391565,"name":"Valerie Richmond‐Reese","orcid":null,"position":4,"is_corresponding":false},{"id":382997,"name":"Sonja Hoover","orcid":"0000-0002-6205-1212","position":5,"is_corresponding":false},{"id":1476697,"name":"Mark Krudy","orcid":null,"position":6,"is_corresponding":false},{"id":382995,"name":"Sujha Subramanian","orcid":"0000-0003-2415-9721","position":7,"is_corresponding":false},{"id":382998,"name":"Florence K. L. Tangka","orcid":"0000-0002-0120-6401","position":0,"is_corresponding":true}],"reference_count":24,"raw_metadata":null,"created_at":"2026-07-19T02:57:19.669553Z","pmid":"40782334","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}